Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact® Survey 2018

Prostate cancer is the most commonly diagnosed visceral cancer in the United States. A majority of cases exhibit an insidious course and nonaggressive tumor behavior. Prostate cancer can manifest as lesions which remain localized, regionally invading or metastasize to lymph nodes, bones, and lungs. Here, we report a unique case of metastatic prostate cancer to the right upper mediastinum, presenting as a paravertebral mass within 2 years of initial tissue diagnosis. Paravertebral spread has not been described for prostate cancer, and herein, we discuss the clinical presentation, diagnostic workup, and possible therapeutic options available in light of the literature.

Download Full-text

PD03-07 THE IMPACT OF SOCIOECONOMIC STATUS, RACE, AND INSURANCE TYPE ON THE RISK OF NEWLY DIAGNOSED METASTATIC PROSTATE CANCER IN THE UNITED STATES

The Journal of Urology ◽

10.1016/j.juro.2017.02.213 ◽

2017 ◽

Vol 197 (4S) ◽

Author(s):

Adam Weiner ◽

Richard Matulewicz ◽

Jeffrey Tosoian ◽

Joseph Feinglass ◽

Edward Schaeffer

Keyword(s):

Prostate Cancer ◽

United States ◽

Socioeconomic Status ◽

Metastatic Prostate Cancer ◽

The United States ◽

Newly Diagnosed ◽

Insurance Type ◽

The Impact

Download Full-text

Patterns of Care of Node-Positive Prostate Cancer Patients Across the United States: A National Cancer Data Base Analysis

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2017.08.004 ◽

2018 ◽

Vol 16 (1) ◽

pp. 35-41.e1 ◽

Cited By ~ 2

Author(s):

Dominic H. Moon ◽

Ram S. Basak ◽

Ronald C. Chen

Keyword(s):

Prostate Cancer ◽

United States ◽

Data Base ◽

Cancer Patients ◽

The United States ◽

National Cancer Data Base ◽

Patterns Of Care ◽

Cancer Data ◽

Node Positive ◽

Base Analysis

Download Full-text

Increasing incidence of metastatic prostate cancer in the United States (2004–2013)

Prostate Cancer and Prostatic Diseases ◽

10.1038/pcan.2016.30 ◽

2016 ◽

Vol 19 (4) ◽

pp. 395-397 ◽

Cited By ~ 111

Author(s):

A B Weiner ◽

R S Matulewicz ◽

S E Eggener ◽

E M Schaeffer

Keyword(s):

Prostate Cancer ◽

United States ◽

Metastatic Prostate Cancer ◽

The United States

Download Full-text

Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States

Cancers ◽

10.3390/cancers13194951 ◽

2021 ◽

Vol 13 (19) ◽

pp. 4951

Author(s):

Umang Swami ◽

Jennifer Anne Sinnott ◽

Benjamin Haaland ◽

Nicolas Sayegh ◽

Taylor Ryan McFarland ◽

...

Keyword(s):

Prostate Cancer ◽

United States ◽

Real World ◽

Comparative Effectiveness ◽

Metastatic Prostate Cancer ◽

Proportional Hazards Model ◽

The United States ◽

Cox Proportional Hazards Model ◽

Real World Data ◽

Hormonal Therapies

Background: Both novel hormonal therapies and docetaxel are approved for treatment of metastatic prostate cancer (mPC; in castration sensitive or refractory settings). Present knowledge gaps include lack of real-world data on treatment patterns in patients with newly diagnosed mPC, and comparative effectiveness of novel hormonal therapies (NHT) versus docetaxel after treatment with a prior NHT. Methods: Herein we extracted patient-level data from a large real-world database of patients with mPC in United States. Utilization of NHT or docetaxel for mPC and comparative effectiveness of an alternate NHT versus docetaxel after one prior NHT was evaluated. Comparative effectiveness was examined via Cox proportional hazards model with propensity score matching weights. Each patient’s propensity for treatment was modeled via random forest based on 22 factors potentially driving treatment selection. Results: The majority of patients (54%) received only androgen deprivation therapy for mPC. In patients treated with an NHT, alternate NHT was the most common next therapy and was associated with improved median overall survival over docetaxel (abiraterone followed by docetaxel vs. enzalutamide (8.7 vs. 15.6 months; adjusted hazards ratio; aHR 1.32; p = 0.009; and enzalutamide followed by docetaxel vs. abiraterone (9.7 vs. 13.2 months aHR 1.40; p = 0.009). Limitations of the study include retrospective design.

Download Full-text